

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Glioma	Stage-specific embryonic antigen-4 (SSEA-4)	<p>Human sample, <i>in vitro</i> and mouse studies suggest an anti-SSEA-4 mAb could be used to treat glioblastoma. In human tissue microarrays, 38 of 55 specimens from patients with glioblastoma expressed SSEA-4, whereas most samples from healthy individuals did not. In cultured human glioblastoma cell lines, an anti-SSEA-4 mAb increased cell death compared with IgG control. In a mouse xenograft model of glioblastoma, the mAb decreased tumor growth compared with IgG control. Next steps include studying the role of SSEA-4 in cancer progression.</p> <p><b>SciBX 7(7); doi:10.1038/scibx.2014.196</b>  <b>Published online Feb. 20, 2014</b></p>	SSEA-4-targeted cancer vaccine patented; patent filed covering anti-SSEA-4 mAb; licensed to an undisclosed company	<p>Lou, Y.-W. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 3, 2014; doi:10.1073/pnas.1400283111</p> <p><b>Contact:</b> Chi-Huey Wong, National Taiwan University, Taipei, Taiwan            e-mail: <a href="mailto:ch Wong@gate.sinica.edu.tw">ch Wong@gate.sinica.edu.tw</a></p>